Steve has taken over the CEO role in late 2022. In addition, Steve has served as Chairman of NexEos Bio since its inception and is a founding member of the company.  Steve Tullman's career in life sciences spans more than 30 years and includes numerous Chairman, CEO, and founding credits, with the creation of ten biotechnology companies. He currently serves as the Managing Member of Nexstone Innovation and Executive Chairman of Uniquity Bio. Steve co-founded NeXeption, Inc. in 2011 and NeXeption, LLC in 2012 to focus on building biotech organizations designed to identify and advance programs with significant unmet medical needs. His previous chairmanships include serving Onspira Therapeutics, Inc. (acquired by Altavant Sciences / Sumitomo Dainippon Pharma in 2019), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), Ralexar Therapeutics, Inc., and Vicept Therapeutics, Inc. until its acquisition by Allergan, Inc. He also served as Chairman, President and CEO of Ceptaris Therapeutics, Inc. until its acquisition by Actelion in 2013. He created Ception Therapeutics, Inc. in 2005 and served as its President and CEO until its acquisition by Cephalon, Inc. in 2010.  Steve received a BS in Accounting from Rutgers University.  

Dr. Himawan is a Managing Director of Essex Woodlands Health Ventures (EWHV).  Dr. Himawan has been at EWHV for the last 20 years, where he was a Managing Director of four funds and served on numerous public and private company boards related to EWHV's investment activity. At EWHV, Dr. Himawan primarily focused on investments in therapeutic-based, pharmaceutical assets (both small molecules and also more complex biopharmaceutical compounds) and led the firm's biotechnology practice. Through these various investments, Dr. Himawan gained an in-depth knowledge of the rapidly-growing antibody industry and the various technologies related to the discovery, manufacture, and clinical development of antibodies (both monoclonal and polyclonal).

Prior to joining EWHV, he began his venture capital career at Seed-One Ventures, an incubator fund which he co-founded in 1996. At Seed-One, he was responsible for managing all of the firm's biotech investments. EWHV invested in one of the Seed-One biotech companies, and, as a result of that interaction, Dr. Himawan joined EWHV in 1999. Prior to co-founding Seed-One, he was a bench scientist at Genzyme Corporation.

Dr. Himawan is also the founder of Point Road Foundation, which currently has a particular emphasis on environmental issues. He received a BS from the Massachusetts Institute of Technology and holds a PhD from Harvard University.

Dennis is currently a Director of Myriad Genetics, Inc., and several private companies. Previously, he was a Senior Vice President, Research and Development at GlaxoSmithKline and, prior to the merger of Glaxo Wellcome and SmithKline Beecham, was a Senior Vice President of SmithKline Beecham. He also served President and CEO of Neose Technologies, Inc.; President of Dr. Reddy’s Laboratories, Inc.; and also held R&D and marketing positions at G.D. Searle & Co., Abbott Laboratories and Eli Lilly & Co.

He earned a BA in Biology from Columbia University, an MD from Georgetown University School of Medicine, and a JD from Harvard Law School. 

Lou Manzi is President of Arrow Consulting and serves as the Head of Strategic HR for  Uniquity Bio.  He was the former Chief People Officer for ISG Technologies, a leader in managed mobility services based in Towson, Maryland and Arlington, Texas before they were purchased in 2021.  Much of his current effort is expended on individual, team and executive coaching as well as creating differentiating capabilities for company leaders.  

​

Additionally, he serves as a recruitment lead for a variety of Fortune 500 organizations. He previously served as Vice President, GSK Talent Solutions for GlaxoSmithKline, and had responsibility for overseeing the strategy and delivery of the global talent sourcing and recruitment functions at GSK. He originally joined SmithKline Beckman Consumer Products as Manager, Government and Public Affairs. He previously served on a variety of Boards including the U.S. Army War College, where he formerly served as Vice President of the Board; Interfaith Health & Support Services of Southern Ocean County Inc; and Robert Michael Communications, Voorhees, NJ.  He is also a past trustee of the Wilkes University Board of Directors and is a former Board Member of The Executive Grapevine, an organization comprised of professionals in Talent Management, London, England.

Lou received his BA from St. Mary’s Seminary College and has done graduate work in the Executive Master’s Program at the University of Pennsylvania.

Chris is President and CEO of Life Sciences Pennsylvania, the life sciences industry advocacy organization for the Commonwealth of Pennsylvania. Before joining Life Sciences Pennsylvania in 2009, he served as Worldwide Vice President of Pharmaceutical Communication and Public Affairs for Johnson & Johnson. Chris currently serves as the Chairman of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and previously served as Vice President for Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA) and held positions at the U.S. Department of Health & Human Services and the White House. He holds a BA from the College of the Holy Cross.

Dr. Siciliano is the current CEO and Co-Founder of viTToria bioTherapeutics, Inc. a cutting-edge, gene-edited cell therapy Company launched with technology developed at the University of Pennsylvania Medical School. Previously, Dr. Siciliano was the CEO and Co-Founder of Invisible Sentinel, Inc. a molecular diagnostic company that was acquired by bioMerieux, a global market leader for diagnostic testing, in February 2019. Dr. Siciliano was the inventor of Invisible Sentinel's proprietary platform technologies, veriFLOW and veriPRO, and led the company's business and R&D initiatives from the concept through acquisition.

​

Dr. Siciliano received a BS degree in Chemistry from Villanova University and shortly thereafter began his scientific career in the department of Microbiology at the University of Pennsylvania Medical School studying host-pathogens interactions. He then earned a PhD in Immunology and Microbial Pathogenesis from Thomas Jefferson University where he studied antigen presentation.

​

Dr. Siciliano is an Entrepreneur in Residence at Agent Capital, and an advisor for Tellus bioVentures and Valley Forge Investment Group. He is the President of the Thomas Jefferson University College of Life Sciences Alumni Board. Nick also serves on several biotech start-up Advisor Boards and is a lecturer in entrepreneurship at local Universities. He holds multiple utility and design patents for diagnostic technologies and has published scientific manuscripts in the fields of bacteriology, virology, immunology, molecular biology, and cancer immunotherapy.